Treehouse Eyes Completes Series Seed Financing

By Staff
Tuesday, March 19, 2019 12:15 AM BOULDER, Colo.—Treehouse Eyes, a startup focused on treating childhood myopia, has closed on a privately led Series Seed financing round. The company, based here, said it will use the funds to expand its geographic footprint in the U.S. and open more myopia treatment centers. Terms of the round were not disclosed. Launched in late 2016, Treehouse Eyes has dedicated myopia management centers in the metro D.C. market with hundreds of myopic children already in treatment.

The Cooper Companies Reports 'Strong Start' to Year as Revenue Increases 6 Percent in First Quarter

By Staff
Wednesday, March 6, 2019 12:24 AM PLEASANTON, Calif.—The Cooper Companies Inc., (NYSE:COO) a leading vision care company, reported Tuesday that companywide revenue for its first quarter, which ended Jan. 31, increased 6 percent year-over-year to $628.1 million. The CooperVision (CVI) segment, which includes the company’s contact lens portfolio, achieved 6 percent growth in revenue, which totaled $470.1 million in the period. The CooperSurgical (CSI) saw its revenue climb 9 percent to $158.0 million, according to the announcement. The company said its diluted earnings per share (on a GAAP basis) totaled $2.07, an increase of 182.6 percent from the year-ago first quarter.

Strong Performance of Kering Eyewear Cited in Kering Group's 'Excellent' 2018 Results

By Staff
Wednesday, February 13, 2019 12:27 AM PADOVA, Italy—Kering Group, the global luxury group overseeing fashion brands Gucci and Saint Laurent, among others, reported strong financial results for 2018 on Tuesday, and noted the “excellent performance” of its Kering Eyewear segment in the period. The company noted that Kering Eyewear sales in 2018 were driven by Gucci and by the success of the new Cartier collection, according to an announcement. “2018 was an excellent year for Kering and its houses,” chairman and chief executive officer François-Henri Pinault said in the announcement.

At Final Meeting, Luxottica Board Highlights Company’s ‘Renewal’ and Strong Period of Performance Under Del Vecchio

By Staff
Thursday, January 31, 2019 12:27 AM MILAN—The board of directors of Luxottica Group S.p.A., meeting here Wednesday for the last session before the company delists from the Italian stock exchange on March 5, used the occasion to acknowledge the company’s strong performance over the 2015-2018 period and to identify the significant strategic initiatives it has executed and which have helped the company attain its leading market position. The stock delisting and final board meeting follow the formation of the new EssilorLuxottica company on Oct. 1, 2018, as VMAIL reported.

Novartis Reports 2018 Results and Says Alcon Is Positioned for ‘Sustainable’ Growth as Standalone Entity

By Staff
Thursday, January 31, 2019 12:24 AM BASEL, Switzerland—Novartis (NYSE: NVS) reported Wednesday that its net sales and core net income grew at a single-digit percentage rate in the fourth quarter, and that it remains on track to spin-off its Alcon eyecare business unit in the first half of this year. Net sales totaled $13.3 billion in the fourth quarter, an increase of 3 percent (6 percent at constant currency rates), driven by volume growth of 9 percent mainly from prescription drugs Cosentyx and Entresto, oncology treatments and the Alcon segment, the announcement noted. Strong volume growth was partly offset by the negative impacts of pricing (-2 percentage points) and generic competition (-1 percentage point).

Safilo Group’s Net Sales Fall 4 Percent in 2018

By Staff
Thursday, January 31, 2019 12:21 AM PADUA, Italy—Safilo Group S.p.A. reported preliminary net sales of €962.9 million for the financial year ended Dec. 31, 2018, a 4.0 percent decrease from year ago at constant exchange rates and a 7.0 percent drop at current exchange rates. This performance is substantially in line with the expectation formulated by the Group on net sales for the year. In Europe, which accounts for nearly half of Safilo’s revenue, net sales totaled €452 million, flat with 2017 at constant exchange rates, but down 1.2 percent at current rates.

EyePoint Pharmaceuticals Added to NASDAQ Biotechnology Index

By Staff
Monday, January 28, 2019 12:15 AM WATERTOWN, Mass.—EyePoint Pharmaceuticals (NASDAQ: EYPT), a specialty biopharma developing innovative ophthalmic products, has been added to the NASDAQ Biotechnology Index (NASDAQ: NBI). The move became effective late last month. The NASDAQ Biotechnology Index is designed to track the performance of a set of securities listed on the NASDAQ market that are classified as either biotech or pharmaceutical, according to the Industry Classification Benchmark (ICB). In a commercial update issued earlier this month, EyePoint said it expects to launch the two new products—Yutiq and Dexycu—in the first quarter, as VMAIL reported

Takeda Completes Acquisition of Shire Earlier Than Expected

By Staff
Tuesday, January 15, 2019 12:24 AM OSAKA, Japan—Takeda Pharmaceutical Company Ltd. (TSE:4502/NYSE:TAK) announced late last week that it has completed its previously announced acquisition of Shire plc. Takeda said that, with the closing of the estimated $62 billion deal, it has become “a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan.” Takeda now will have an expanded geographic footprint and a leading position in Japan and the U.S., and will be in position to bring its innovative medicines to approximately 80 countries and/or regions with dedicated employees worldwide, the announcement noted.

Ocular Therapeutix Added to Nasdaq Biotechnology Index

By Staff
Friday, December 28, 2018 12:18 AM BEDFORD, Mass.—Ocular Therapeutix Inc. (NASDAQ: OCUL), a biopharmaceutical company focused on developing and commercializing innovative therapies for diseases and conditions of the eye, has been added to the Nasdaq Biotechnology Index (NASDAQ: NBI), according to a recent announcement. Ocular Therapeutix’s addition to the NBI became effective Monday, Dec. 24. Ocular Therapeutix's first product, ReSure Sealant, is FDA-approved to seal corneal incisions following cataract surgery. Ocular Therapeutix is developing innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology, according to the company’s recent announcement.

Zeiss Group Reports Record Revenues and Earnings

By Staff
Wednesday, December 19, 2018 12:21 AM STUTTGART, Germany—The Zeiss Group reported a strong performance in fiscal year 2017/18, the period ending Sept. 30, 2018. The company said it achieved record-breaking revenue and earnings. Revenue increased by 9 percent to €5.817 billion (previous year: €5.348 billion). After currency adjustments, revenue rose by 12 percent. Earnings performance helped fully compensate for the unfavorable currency effects. Thus, at €772 million, earnings before interest and taxes (EBIT) were slightly higher than the previous year (€770 million). The EBIT margin was 13 percent. Order intake increased by 7 percent, totaling €6.046 billion.

Multibrands Exercises Option Rights Relating to Safilo Group’s Capital Increase

By Staff
Wednesday, December 5, 2018 12:21 AM PADUA, Italy—Safilo Group S.p.A. said Tuesday afternoon that its major shareholder, Multibrands Italy BV, a subsidiary of HAL Holding NV, exercised its option rights on Monday and paid for subscription of the new shares relating to its existing holding (approximately 41.6 percent) of an ongoing capital increase. The amount involved in the exercise of the option rights totaled approximately €62.4 million, according to the Safilo announcement. Monday, Dec. 3, was the first day of the offering period and first day that Multibrands could exercise its options, under terms approved late last week by Italy’s CONSOB, as VMAIL reported.

EyeSouth Partners Continues Expansion With Georgia Eye Associates Investment

By Staff
Tuesday, November 20, 2018 12:27 AM ATLANTA—EyeSouth Partners, an eyecare-focused physician services organization formed by Shore Capital Partners,  has completed a strategic partnership with Georgia Eye Associates.

National Vision’s Secondary Offering Pricing Set

By Staff
Tuesday, November 20, 2018 12:15 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported late last week that the public price of its previously announced secondary offering will be $40.50 per share.

National Vision Reports 67th Straight Quarter of Same-Store Sales Growth

By Staff
Wednesday, November 14, 2018 12:24 AM DULUTH, Ga.—National Vision Holdings Inc. (NASDAQ: EYE) reported Tuesday that its sales rose 11.9 percent to $387.4 million in the third quarter, which ended Sept. 29. The increase was driven, in part, by a same-store sales increase of 7 percent (6.8 percent on an adjusted basis), which marked the 67th consecutive quarter of positive comparable-store sales growth for National Vision, according to an announcement from the company. Sales in the year-ago quarter totaled $346.1 million.

New Look Reports Record Results for 3Q 2018

By Staff
Wednesday, November 14, 2018 12:21 AM MONTREAL—Canadian optical retailer New Look Vision Group (TSX: BCI) reported record results for the third quarter ended Sept. 29, 2018. Revenues increased by 32.0 percent over last year to $72.9 million, mainly as a result of New Look’s acquisition of the Iris group in 2017, as well as comparable store sales growth. Comparable store sales orders rose 0.2 percent compared to the third quarter of last year, marking New Look’s 17th consecutive quarter of comparable store sales growth.